UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

I	FORM 10-Q	
Mark One)		
QUARTERLY REPORT PURSUANT TO SECTION 13 O	OR 15(d) OF THE SECUE	RITIES EXCHANGE ACT OF 1934
For the qu	uarterly period ended Jui	ne 30, 2024
	OR	
TRANSITION REPORT PURSUANT TO SECTION 13 C	OR 15(d) OF THE SECUI	RITIES EXCHANGE ACT OF 1934
Fo	or the transition period fron	n to
Commis	ssion file number 000-563	42
VERANO	HOLDINGS	CORP.
(Exact name of r	egistrant as specified in	n its charter)
British Columbia, Canada		98-1583243
(State or other jurisdiction of incorporation or organization	1)	(I.R.S. Employer Identification No.)
224 W Hill Street, Suite 400, Chicago, Illinois		60610
(Address of Principal Executive Offices)		(Zip Code)
	(312) 265-0730	
(Registrant's tele	phone number, including	g area code)
	N/A	
(Former name, former address	and former fiscal year, if	changes since last report)
curities registered pursuant to Section 12(b) of the Act:		
TT'-1 0 1 1	Trading Symbol	Name of each exchange on which registered
Title of each class		

the past 90 days. Yes ⊠ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⊠ No □

Table of Contents

in Rule 12b-2	th company. See the definitions of "larg of the Exchange Act.	ge accelerated filer," "a	accelerated filer," "smaller reporting company,"	smaller reporting company, or a 'and "emerging growth company
	Large accelerated filer	\boxtimes	Accelerated filer	
	Non-accelerated filer		Smaller reporting company	
			Emerging growth company	
	<u> </u>		in Rule 12b-2 of the Exchange Act). Yes \(\simeg\) No long shares and no Class B proportionate voting s	
As of August 2				

TABLE OF CONTENTS

		Pages
Part I - Financial In	oformation	1
Item 1.	Unaudited Interim Condensed Consolidated Financial Statements	1
	Condensed Consolidated Balance Sheets	<u>2</u>
	<u>Unaudited Interim Condensed Consolidated Statements of Operations</u>	<u>3</u>
	Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity	<u>4</u>
	Unaudited Interim Condensed Consolidated Statements of Cash Flows	<u>6</u>
	Notes to Unaudited Interim Condensed Consolidated Financial Statements	<u>7</u>
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>28</u>
<u>Item 3.</u>	Quantitative and Qualitative Disclosures About Market Risk	<u>38</u>
Item 4.	Controls and Procedures	<u>38</u>
Part II - Other Infor	<u>rmation</u>	<u>39</u>
Item 1.	<u>Legal Proceedings</u>	<u>39</u>
Item 1A.	Risk Factors	<u>39</u>
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>39</u>
<u>Item 3.</u>	<u>Defaults Upon Senior Securities</u>	<u>39</u>
<u>Item 4.</u>	Mine Safety Disclosures	<u>39</u>
<u>Item 5.</u>	Other Information	<u>39</u>
<u>Item 6.</u>	<u>Exhibits</u>	<u>40</u>
<u>Signatures</u>		<u>41</u>

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q (this "Form 10-Q") contains "forward-looking information" and "forward-looking statements" within the meaning of United States securities laws (together, "forward-looking statements"). All statements, other than statements of historical fact, made by the Company or its affiliates that address activities, events or developments that the Company or its affiliates expect or anticipate will or may occur in the future are forward-looking statements, including, but not limited to, statements preceded by, followed by or that include words such as "may," "will," "would," "could," "should," "believes," "assumes," "estimates," "projects," "potential," "expects," "plans," "intends," "anticipates," "targeted," "continues," "forecasts," "designed," "goal," "progress," or the negative of those words or other similar or comparable words.

The forward-looking statements contained herein are based on certain key expectations and assumptions, including, but not limited to, expectations and assumptions concerning:

- our ability to obtain, maintain and renew licenses and other regulatory approvals in all states and localities of our operations and planned operations on a timely basis;
- government regulations, including future U.S. state and federal legislative and regulatory developments involving medical and adult-use cannabis and the timing thereof;
- our outlook on our expansion and growth of business and operations;
- our ability to achieve our goals, business plans and strategy;
- our ability to access capital and obtain necessary financing to pursue our growth and business plans;
- our operational results and other financial and business conditions and prospects;
- the timing and completion of acquisitions and other commercial transactions;
- the integration and operation of acquired businesses;
- the timing and amount of capital expenditures;
- the availability of facilities, equipment, skilled labor and services needed for cannabis operations;
- demand, developments and trends in the medical and adult-use cannabis industry;
- competition in the cannabis industry in the markets in which we operate or plan to operate;
- the medical benefits, viability, safety, efficacy, and dosing of cannabis;
- the size of the medical cannabis market and the adult-use cannabis market in each state; and
- conditions in general economic and financial markets.

Forward-looking statements may relate to future financial conditions, results of operations, plans, strategies, objectives, performance or business developments. These statements speak only as at the date they are made and are based on information currently available and on the then-current expectations of the party making the statement and assumptions concerning future events, which are subject to a number of known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from that which was expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to:

- the illegality of cannabis under federal law, the U.S. federal regulatory landscape and enforcement related to medical or adult-use cannabis, including political risks, civil asset forfeiture and regulation by additional regulatory authorities;
- regulatory and political changes to U.S. federal, state and local laws related to medical or adult-use cannabis, including political risks and regulation by additional regulatory authorities;
- our limited operating history;
- the impacts of economic uncertainty stemming from disruptions in U.S. and global markets, inflation, rising interest rates, and changes in consumer and business confidence:
- our outstanding indebtedness and potential future indebtedness;
- any potential changes in our liquidity due to potential for instability in market and economic conditions and adverse developments to financial institutions;
- reliance on key management;
- market acceptance of existing and new products and potential returns or recalls of our products;
- · customer acceptance of our brand portfolio;
- the accuracy of our forecasted demand for our products;
- the potential for fraudulent activity by employees, contractors and consultants;
- our exposure to growth-related operational and execution risks;
- potential negative findings in our clinical research with respect to our products;
- our ongoing litigation matter with Goodness Growth Holdings, Inc;

- potential product liability claims;
- our exposure to natural phenomena and resulting potential uninsured or under insured losses;
- our structure and our resulting reliance on the performance of our subsidiaries and affiliates;
- our expansion-by-acquisition strategy;
- · our ability to acquire businesses and cannabis licenses in desired markets and the integration and operation of acquired businesses;
- the typically limited operations of businesses we acquire;
- the unconventional due diligence process in the cannabis industry;
- our ability to acquire and lease properties suitable for the cultivation, production and sale of cannabis;
- potential limited representations and warranties of businesses we may acquire;
- our acquisition of businesses in developing cannabis markets;
- our lack of portfolio diversification;
- our use of joint ventures, strategic partnerships and alliances;
- our contractual relationships with our consolidated variable interest entities;
- existing competition and new market entrants;
- the introduction of synthetic alternatives to cannabis products by pharmaceutical and other companies;
- the immaturity of the cannabis industry and limited comparable, competitive and established industry best practices;
- the availability of and our reliance on third-party suppliers, service providers, contractors and manufacturers;
- · wholesale and retail price fluctuations;
- public opinion and perception of the cannabis industry;
- the availability of raw or other materials;
- rising or volatile energy costs;
- agricultural and environmental risks and the impacts of environmental regulations on the cannabis industry and environmental protections;
- physical security risks, such as theft;
- potential scrutiny from Canadian authorities;
- disparate state-by-state regulatory landscapes and licensing regimes for medical and adult-use cannabis;
- the difficulties cannabis businesses face accessing and maintaining banking or financial services due to federal regulations;
- the cost and difficulty of complying with various regulatory schemes;
- the impact of state social equity legislation as it relates to the cannabis industry;
- the risk of high bonding and insurance costs;
- environmental regulations;
- effects of changes in laws and policies governing employees and by union organizing activity;
- potential divestment of licenses if required by regulatory authorities;
- our dependency on the banking industry;
- · required public disclosure and governmental filings containing personal information of our officers, investors and other stakeholders;
- potential findings by regulatory authorities that one of shareholders is unsuitable;
- the risk that our directors, officers, employees or investors are barred from entering the U.S.;
- the ability to, and constraints on, promoting and marketing cannabis products;
- potential U.S. Food and Drug Administration governance of the cannabis industry;
- the potential limitations on our ability to enforce our contracts or any liens granted to us;
- the potential lack of access to federal bankruptcy protections in the U.S.;
- reliance on information technology systems, the potential disclosure of personal information of patients and customers and cybersecurity risks;
- · our reliance on third-party software providers;
- cost related to preserving our brand identity;
- our ability to protect our intellectual property due to limited intellectual property protection available for cannabis products and the potential infringement by third parties;
- potential infringement or misappropriation claims;
- the risk of receiving no return on our securities;
- our elimination of monetary liability and indemnification rights against our directors, officers and employees under British Columbia law;
- · our dual class capital structure with Class A subordinate voting shares and Class B proportionate voting shares;
- the time and resources necessary to comply with corporate governance practices and securities rules and regulations in the U.S. and Canada;
- our management's ability to maintain effective internal controls;

Table of Contents

- · our remediation plan and ability to remediate the material weaknesses in our internal controls over financial reporting;
- potential dilution if we issue additional Subordinate Voting Shares or Proportionate Voting Shares;
- market perception of sales of a substantial amount of Subordinate Voting Shares;
- transfer restrictions on our Subordinate Voting Shares;
- price volatility of our Subordinate Voting Shares;
- our shareholders' limited participation in our affairs;
- our expectation to not declare or pay out dividends;
- the concentration of our voting control;
- the taxation of cannabis companies in the U.S., including the impact of Section 280E of the Internal Revenue Code of 1986, as amended; and
- other risks described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission on March 15, 2024, as more particularly described under the heading "Item 1A. Risk Factors" therein.

Although we believe that the expectations and assumptions on which forward-looking statements are based are reasonable at the time made, undue reliance should not be placed on the forward-looking statements, because no assurance can be given that they will prove to be correct. Forward-looking statements address future events and conditions, and thus involve inherent risks and uncertainties. Readers are cautioned that the above list of cautionary statements is not exhaustive.

The cannabis industry involves risks and uncertainties that are subject to change based on various factors. Certain forward-looking statements contained herein concerning the cannabis industry and our general expectations concerning the cannabis industry are based on estimates prepared by us using data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of the cannabis industry. Such data is inherently imprecise.

Consequently, all forward-looking statements made in this Form 10-Q and our other documents are qualified by such cautionary statements and there can be no assurance that the anticipated results or developments will actually be realized or, even if realized, that they will have the expected consequences to or effects on us. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required under applicable securities legislation.

Table of Contents

PART I - FINANCIAL INFORMATION

ITEM 1. UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

VERANO HOLDINGS CORP. **Condensed Consolidated Balance Sheets**

(\$ in Thousands)

	June 30, 2024		ecember 31, 2023
	(Unaudited)		
ASSETS			
Current Assets:			
Cash and Cash Equivalents	\$ 130,052	\$	174,76
Accounts Receivable, net	43,206		38,98
Held for Sale Assets	220		1,95
Inventory	169,361		155,76
Prepaid Expenses and Other Current Assets	 14,724		22,73
Total Current Assets	357,563		394,19
Property, Plant and Equipment, net	507,447		501,30
Right of Use Assets, net	90,898		93,45
Intangible Assets, net	1,040,572		1,086,14
Goodwill	231,291		231,29
Deposits and Other Assets	 11,282		12,34
TOTALASSETS	\$ 2,239,053	\$	2,318,74
LIABILITIES AND SHAREHOLDERS' EQUITY			
LIABILITIES			
Current Liabilities:			
Accounts Payable	\$	\$	31,28
Accrued Liabilities	65,778		66,76
Income Tax Payable	251,242		248,47
Current Portion of Lease Liabilities	10,207		9,75
Current Portion of Debt	4,055		52,00
Acquisition Consideration Payable	 4,106		3,91
Total Current Liabilities	 360,591		412,18
Long-Term Liabilities:			
Debt, net of Current Portion	391,723		393,63
Lease Liabilities, net of Current Portion	86,778		87,39
Deferred Income Taxes	174,790		182,21
Other Long-Term Liabilities	 3,779		3,22
Total Long-Term Liabilities	657,070		666,47
TOTAL LIABILITIES	\$ 1,017,661	\$	1,078,66
SHAREHOLDERS' EQUITY	 1,221,392		1,240,08
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 2,239,053	\$	2,318,74

Unaudited Interim Condensed Consolidated Statements of Operations

(\$ in Thousands except shares and per share amounts)

	For the Three Months End		hs Ended June 30,		For the Six Month	hs Ended June 30,		
		2024		2023		2024		2023
Revenues, net of Discounts	\$	222,390	\$	234,115	\$	443,696	\$	461,175
Cost of Goods Sold, net		108,050		118,924		216,396		236,799
Gross Profit		114,340		115,191		227,300		224,376
Selling, General, and Administrative Expenses		87,074		84,660		177,363		159,908
Loss from Investments in Associates				(101)				(261)
Income from Operations		27,266		30,430		49,937		64,207
Other Income (Expense):								
Loss on Disposal of Property, Plant and Equipment		_		(388)		(143)		(322)
Loss on Debt Extinguishment		(3,068)		_		(3,068)		(663)
Interest Expense, net		(14,237)		(14,013)		(29,351)		(29,918)
Other Income (Expense), net		(1,195)		(1,411)		(1,954)		397
Total Other Income (Expense), net		(18,500)		(15,812)		(34,516)		(30,506)
Income Before Provision for Income Taxes		8,766		14,618		15,421		33,701
Provision For Income Taxes		(30,530)		(27,679)		(42,007)		(55,999)
Net Loss Attributable to Verano Holdings Corp. & Subsidiaries	\$	(21,764)	\$	(13,061)	\$	(26,586)	\$	(22,298)
Net Loss per share – basic & diluted	\$	(0.06)	\$	(0.04)	\$	(0.08)	\$	(0.07)
Basic & Diluted – weighted average shares outstanding		345,020,397		342,533,911		345,483,701		342,006,385

Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity

(\$ in Thousands)

	Subordinate Voting Shares (as converted)	Shares Comprehensive Accumulated		Comprehensive Accu		Accumulated Earnings (Deficit)		Total	
Balance as of April 1, 2023	342,330,264	\$	1,670,116	\$	(9)	\$	(333,636)	\$ 1,336,471	
Share-based compensation	824,625		3,976		_		_	3,976	
Issuance of shares to relieve liability obligations	212,625		(1,043)		_		_	(1,043)	
Foreign Currency Translation Adjustment	_		_		1		_	1	
Net Loss		_			<u> </u>		(13,061)	(13,061)	
Balance as of June 30, 2023	343,367,514	\$	1,673,049	\$	(8)	\$	(346,697)	\$ 1,326,344	
	Subordinate Voting Shares (as converted)		Share Capital	A	accumulated Other Comprehensive Income (Loss)		Accumulated arnings (Deficit)	Total	
Balance as of April 1, 2024	Shares	\$		A	Comprehensive			\$ Total 1,238,916	
Balance as of April 1, 2024 Share-based compensation	Shares (as converted)	\$	Capital		Comprehensive Income (Loss)	E	arnings (Deficit)	\$	
• '	Shares (as converted) 344,163,149	\$	Capital 1,685,483		Comprehensive Income (Loss)	E	arnings (Deficit)	\$ 1,238,916	
Share-based compensation	Shares (as converted) 344,163,149	\$	Capital 1,685,483		Comprehensive Income (Loss)	E	arnings (Deficit)	\$ 1,238,916	
Share-based compensation Foreign Currency Translation Adjustment Contingent consideration & other adjustments to	Shares (as converted) 344,163,149	\$	Capital 1,685,483		Comprehensive Income (Loss)	E	arnings (Deficit)	\$ 1,238,916	

Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity (Continued) (\$ in Thousands)

	Subordinate Voting Shares (as converted)	Share Capital	1	Accumulated Other Comprehensive Income (Loss)	E	Accumulated arnings (Deficit)	Total
Balance as of January 1, 2023	339,983,374	\$ 1,665,957	\$	(8)	\$	(324,399)	\$ 1,341,550
Share-based compensation	942,573	4,482		_		-	4,482
Issuance of shares to relieve liability obligations, net	816,021	2,610		_		_	2,610
Foreign Currency Translation Adjustment	_	_		_		_	_
Contingent consideration & other adjustments to purchase accounting	1,625,546	_		_		_	_
Net Loss			_			(22,298)	(22,298)
Balance as of June 30, 2023	343,367,514	\$ 1,673,049	\$	(8)	\$	(346,697)	\$ 1,326,344
	Subordinate Voting Shares (as converted)	Share Capital	1	Accumulated Other Comprehensive Income (Loss)]	Accumulated Earnings (Deficit)	Total
Balance as of January 1, 2024	344,074,096	\$ 1,681,840	\$	(13)	\$	(441,747)	\$ 1,240,080
Share-based compensation	2,311,867	7,883		_		_	7,883
Foreign Currency Translation Adjustment	_	_		15		_	15
Contingent consideration & other adjustments to purchase accounting	31,181	_		_		_	_
Net Loss		 				(26,586)	 (26,586)
Balance as of June 30, 2024	346,417,144	\$ 1,689,723	\$	2	\$	(468,333)	\$ 1,221,392

Unaudited Interim Condensed Consolidated Statements of Cash Flows

(\$ in Thousands)

	Six Months E	ded June 30,	
	2024	2023	
CASH FLOW FROM OPERATING ACTIVITIES			
Net loss attributable to Verano Holdings Corp. and Subsidiaries	\$ (26,586)	\$ (22,298)	
Adjustments to reconcile net loss to net cash provided by operating activities:			
Depreciation and amortization	71,285	70,293	
Right of use assets amortization	6,816	5,189	
Loss on disposal of property, plant and equipment	143	322	
Loss on debt extinguishment	3,068	663	
Decrease in fair value of contingent consideration	_	(3,466)	
Stock based compensation	8,244	4,292	
Other, net	4,799	3,270	
Changes in operating assets and liabilities:			
Accounts receivable, net	(5,059)	(11,302	
Inventory	(13,633)	19,833	
Accounts payable	(9,874)	(8,707	
Income tax payable	2,772	(25,876	
Other assets, net	9,451	5,956	
Other liabilities, net	(12,464)	2,571	
NET CASH PROVIDED BY OPERATING ACTIVITIES	38,962	40,740	
CASH FLOW FROM INVESTING ACTIVITIES			
Purchases of property, plant and equipment	(28,215)	(16,541	
Proceeds from disposal of assets	(20,213)	2,172	
NET CASH USED IN INVESTING ACTIVITIES	(28,215)	(14,369	
	· · · ·		
CASH FLOW FROM FINANCING ACTIVITIES			
Acquisition of business, net of cash acquired	(32)	(13,250	
Proceeds from issuance of debt	_	32,167	
Principal repayments of debt	(54,302)	(26,876	
Debt issuance costs paid	_	(684	
Payment of debt extinguishment	(1,000)	_	
Other financing activities	(136)		
NET CASH USED IN FINANCING ACTIVITIES	(55,470)	(8,643	
NET CHANGE IN CASH AND CASH EQUIVALENTS	(44,723)	17,728	
Effects of exchange rate fluctuations on cash and cash equivalents	15		
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	174,760	84,851	
CASH AND CASH EQUIVALENTS, END OF PERIOD	\$ 130,052	\$ 102,579	
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION			
Interest paid, net	\$ 26,758	\$ 30,191	
Issuance of shares to relieve liability obligations, net	ş	\$ 2,610	

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

1. OVERVIEW AND BASIS OF PRESENTATION

(a) Description of Business

Unless otherwise stated or the context requires otherwise, references herein to the "Company," "Verano," "we," "us," and "our" mean Verano Holdings Corp. and its direct and indirect subsidiaries, and controlled and managed entities.

The Company is a vertically integrated cannabis operator that focuses on limited-licensed markets in the United States ("U.S."). As a vertically integrated operator, the Company owns, operates, manages, controls, and/or has licensing, consulting or other commercial agreements with cultivation, processing, and retail licenses across 13 state markets (Arizona, Arkansas, Connecticut, Florida, Illinois, Maryland, Massachusetts, Michigan, Nevada, New Jersey, Ohio, Pennsylvania, and West Virginia).

The Company also conducts pre-licensing activities in other markets. In these markets, the Company has either applied for licenses, or plans on applying for licenses, but does not currently own or manage any cultivation, processing, or retail licenses.

The Company's Class A subordinate voting shares, no par value (the "Subordinate Voting Shares") are listed on Cboe Canada ("Cboe") under the ticker symbol "VRNO" and are quoted in the United States on the OTCQX marketplace operated by the OTC Market Group, under the ticker symbol "VRNOF".

The Company's corporate headquarters is located at 224 W Hill Street, Suite 400, Chicago, Illinois 60610.

(b) Basis of Presentation

The accompanying Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Unless otherwise indicated, all references to "\$" or "US\$" in this Form 10-Q refer to United States dollars, and all references to "C\$" refer to Canadian dollars. These Unaudited Interim Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2023 (the "2023 Annual Audited Financials"), included in the Company's Annual Report on Form 10-K filed with the SEC on March 15, 2024 (the "Form 10-K"). Certain prior year amounts have been reclassified to conform to the current year's presentation, which the Company does not consider to be material. The accompanying Unaudited Interim Condensed Consolidated Financial Statements include the accounts of Verano Holdings Corp. and its direct and indirect subsidiaries as well as the accounts of any entities over which the Company has a controlling financial interest in accordance with Accounting Standards Codification ("ASC") 810 Consolidation. The preparation of the Company's Unaudited Interim Condensed Consolidated Financial Statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of assets and liabilities in such financial statements and in the accompanying notes. Actual results may differ materially from these estimates. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the 2024 full year or any future periods. The accompanying consolidated balance sheet as of December 31, 2023 has been derived from the audited consolidated balance sheet as of December 31, 2023 contained in the 2023 Annual Audited Financials included in the Form 10-K.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

1. OVERVIEW AND BASIS OF PRESENTATION (Continued)

(c) Basis of Consolidation

The Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with GAAP and include the accounts of the Company and its subsidiaries, as well as the accounts of any entities over which the Company has a controlling financial interest in accordance with ASC 810 *Consolidation*. All transactions and balances between these entities have been eliminated upon consolidation.

(d) Significant Accounting Policies

There have been no changes to the Company's significant accounting policies as described in *Note 2 - Significant Accounting Policies* to the 2023 Annual Audited Financials included in the Form 10-K.

(e) Earnings (Loss) per Share

Basic earnings (loss) per share is calculated using the treasury stock method, by dividing the net earnings (losses) attributable to shareholders by the weighted average number of shares (including the Company's Class B proportionate voting shares, no par value (the "Proportionate Voting Shares") on an as converted to Subordinate Voting Shares basis of 100 Subordinate Voting Shares to one Proportionate Voting Share) outstanding during each of the periods presented. Contingently issuable shares (including shares held in escrow) are not considered outstanding shares and consequently are not included in the earnings (loss) per share calculations. Diluted income per share is calculated by adjusting the weighted average number of shares outstanding to assume conversion of all dilutive potential shares.

To determine diluted income (loss) per share, the Company assumes that any proceeds from the exercise of dilutive share options would be used to repurchase shares at the average market price during the period. The diluted income (loss) per share calculation excludes any potential conversion of share options and convertible debt, if any, that would increase earnings per share or decrease loss per share. No potentially dilutive share equivalents were included in the computation of diluted loss per share for the three and six months ended June 30, 2024 and 2023 because their impact would have been anti-dilutive.

(f) Recently Issued Accounting Standards

In November 2023, the Financial Accounting Standards Board issued Accounting Standards Update 2023-07 - ASC 280 Segment Reporting - Improvements to Reportable Segment Disclosures ("ASU 280"), which extends the existing requirements for annual disclosures to quarterly periods, and requires that both annual and quarterly disclosures present segment expenses using line items consistent with information regularly provided to the chief operating decision maker. ASU 280 is effective for annual periods beginning after December 15, 2023 and quarterly periods beginning after December 15, 2024. The Company does not expect implementation of the new disclosure guidance to have a material impact to its consolidated financial statements.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

2. INVENTORY

The Company's inventory consists of the following as of June 30, 2024 and December 31, 2023:

	June 30, 2024	December 31, 2023
Raw Materials	\$ 5,745	\$ 5,336
Work in Process	123,201	114,620
Packaging and Miscellaneous	8,273	7,899
Finished Goods	32,142	27,913
Total Inventory	\$ 169,361	\$ 155,768

During the year ended December 31, 2023, the Company classified Packaging and Miscellaneous as a component of Prepaid Expenses and Other Current Assets on the Consolidated Balance Sheets as of December 31, 2023. Packaging and Miscellaneous has been reclassified to Inventory in the Unaudited Interim Condensed Consolidated Balance Sheets as of June 30, 2024, to better reflect the character of the underlying assets. Prior periods have been reclassified to conform to the current period presentation.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

3. PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment and related accumulated depreciation consists of the following as of June 30, 2024 and December 31, 2023:

	 June 30, 2024	_	December 31, 2023
Land	\$ 30,934	\$	30,934
Buildings and Improvements	194,274		194,274
Furniture and Fixtures	20,540		19,884
Computer Equipment and Software	27,284		25,861
Leasehold Improvements	235,855		230,877
Tools and Equipment	91,839		90,386
Vehicles	4,390		4,373
Assets Under Construction (1)	62,839		39,844
Total Property, Plant and Equipment, Gross	667,955		636,433
Less: Accumulated Depreciation	(160,508)		(135,129)
Total Property, Plant and Equipment, Net	\$ 507,447	\$	501,304

⁽¹⁾ Assets under construction represent construction in progress related to facilities not yet completed or otherwise not placed in service.

For the three months ended June 30, 2024 and June 30, 2023, depreciation expense included in costs of goods sold totaled \$8,830 and \$8,532, respectively. For the three months ended June 30, 2024 and June 30, 2023, depreciation expense included in selling, general, and administrative expense totaled \$4,116 and \$3,840, respectively.

For the six months ended June 30, 2024 and June 30, 2023, depreciation expense included in costs of goods sold totaled \$17,554 and \$17,056, respectively. For the six months ended June 30, 2024 and June 30, 2023, depreciation expense included in selling, general, and administrative expense totaled \$8,157 and \$7,507, respectively.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

4. INTANGIBLE ASSETS AND GOODWILL

Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value as of the acquisition date. Amortization of definite life intangible assets is provided on a straight-line basis over their estimated useful lives. The estimated useful lives, residual values, and amortization methods for intangible assets are reviewed by the Company at each year end, and any changes in estimates are accounted for prospectively.

As of June 30, 2024, intangible assets consisted of the following:

	Licenses		Tradenames		Technology		Total
Cost							
Balance as of January 1, 2024	\$	1,269,326	\$	54,166	\$	6,431	\$ 1,329,923
Balance as of June 30, 2024	\$	1,269,326	\$	54,166	\$	6,431	\$ 1,329,923
Accumulated Amortization							
Balance as of January 1, 2024		225,751		15,001		3,025	243,777
Amortization		42,344		2,711		519	 45,574
Balance as of June 30, 2024	\$	268,095	\$	17,712	\$	3,544	\$ 289,351
Net Book Value							
Balance as of January 1, 2024		1,043,575		39,165		3,406	 1,086,146
Balance as of June 30, 2024	\$	1,001,231	\$	36,454	\$	2,887	\$ 1,040,572

The following table outlines the estimated annual amortization expense related to intangible assets as of June 30, 2024:

Year Ending December 31:	Estimated Amortization
2024 (Remaining)	\$ 45,574
2025	91,149
2026	90,434
2027	90,360
2028	90,342
Thereafter	632,713
Total	\$ 1,040,572

The changes in the carrying amount of goodwill, by reportable segment, for the six months ended June 30, 2024 were as follows:

	Janu	ary 1, 2024	 Impairment	ourchase price allocation	Acquisitions	 June 30, 2024
Cultivation	\$	49,318	\$ 	\$ 	\$ 	\$ 49,318
Retail		181,973	_	_	_	181,973
Total	\$	231,291	\$ _	\$ _	\$ _	\$ 231,291

A J:---4--- ---4-- 4--

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

5. EARNINGS (LOSSES) PER SHARE

The Company presents basic earnings (losses) per share. Basic earnings (losses) per share is calculated by dividing the earnings (loss) attributable to shareholders by the weighted average number of Subordinate Voting Shares (with outstanding Proportionate Voting Shares, if any, accounted for on an as converted to Subordinate Voting Shares basis) outstanding during the periods presented. Diluted earnings (losses) per share is computed based on the weighted average number of Subordinate Voting Shares (with outstanding Proportionate Voting Shares, if any, accounted for on an as converted to Subordinate Voting Shares basis) outstanding, to the extent dilutive.

The computations of net earnings (loss) per share on a basic and diluted basis, including reconciliations of the numerators and denominators, for the three and six months ended June 30, 2024 and June 30, 2023 were as follows:

	Three Months Ended June 30,					Six Months Ended June 30,				
		2024		2023		2024		2023		
Numerator										
Net Loss attributable to Verano Holdings Corp.	\$	(21,764)	\$	(13,061)	\$	(26,586)	\$	(22,298)		
Denominator										
Basic										
Weighted-average shares outstanding – basic		345,020,397		342,533,911		345,483,701		342,006,385		
<u>Diluted</u>										
Weighted-average shares outstanding - diluted		345,020,397		342,533,911		345,483,701		342,006,385		
Net Loss per share - basic & diluted	\$	(0.06)	\$	(0.04)	\$	(0.08)	\$	(0.07)		

Potentially dilutive securities of approximately 3,833,306 and 3,753,438 for the three and six months ended June 30, 2024, respectively, were not included in the computation of diluted earnings per share because their effect would have been anti-dilutive.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

6. TRANSACTIONS

Business Combinations

The Company has determined that the acquisitions described below are business combinations under ASC Topic 805, *Business Combinations*. Acquisitions that are determined to be the acquisition of a business are accounted for by applying the acquisition method, whereby the assets acquired, and the liabilities assumed are recorded at their fair values at the date of acquisition with any excess of the aggregate consideration over the fair values of the identifiable net assets allocated to goodwill. Operating results for the companies acquired have been included in these Unaudited Interim Condensed Consolidated Financial Statements from the date of the acquisition. Any goodwill recognized is attributed based on reporting units.

The purchase price allocations for the acquisitions reflect various fair value estimates and analyses which are subject to change within the measurement period, which is the one-year period subsequent to the acquisition date. The primary areas of the purchase price allocation that are subject to change relate to the fair value of certain tangible assets, the value of intangible assets acquired, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair value of the net assets acquired at the acquisition date during the measurement period.

Measurement period adjustments that the Company determined to be material will be applied prospectively in the Company's future consolidated financial statements, and depending on the nature of the adjustments, other periods subsequent to the period of acquisition could be affected.

WSCC, Inc.

On July 6, 2021, Verano entered into a merger agreement to acquire 100% of the equity interests of WSCC, Inc ("Sierra Well"). Sierra Well held cannabis licenses that allow it to cultivate, produce and sell medical and recreational cannabis products in the state of Nevada, including sales through its retail dispensaries located in Carson City and Reno. The transaction closed on September 7, 2022.

During the quarter ended March 31, 2024, the Company paid cash consideration of \$32 and issued 31,181 Subordinate Voting Shares to the former shareholders of Sierra Well, which had been held back to secure indemnification obligations of such shareholders. As of June 30, 2024, all consideration related to the acquisition has been paid.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

7. DEBT

As of June 30, 2024, and December 31, 2023 debt consisted of the following:

	June 30, 2024				
Credit Facility	\$	296,850	\$	348,950	
Secured Promissory Notes		1,552		1,582	
Mortgage Loans		109,291		111,221	
Vehicle and Equipment Loans		840		1,081	
Unamortized Debt Issuance Costs		(12,755)		(17,192)	
Total Debt	\$	395,778	\$	445,642	
Less: Current Portion of Debt	, <u> </u>	4,055		52,005	
Total Long-Term Debt, net	\$	391,723	\$	393,637	

Credit Facility

On October 27, 2022, Verano and certain of its subsidiaries and affiliates from time-to-time party thereto (collectively, the "Borrowers"), entered into a Credit Agreement (the "2022 Credit Agreement") with Chicago Atlantic Admin, LLC ("Chicago Atlantic"), as administrative agent for the lenders, and the lenders from time-to-time party thereto (the "Lenders"), pursuant to which the Lenders advanced the Borrowers a \$350,000 senior secured term loan, all of which was used to repay the principal indebtedness outstanding under the Company's previous senior secured term loan credit facility. In connection with such repayment, such previous credit facility was terminated and is no longer in force or effect.

The 2022 Credit Agreement provides the Borrowers with the right, subject to conditions, to request an additional incremental term loan in the aggregate principal amount of up to \$100,000; provided that the Lenders elect to fund such incremental term loan. Beginning in October 2023, the loan requires scheduled amortization payments of \$350 per month and the remaining principal balance is due in full on October 30, 2026.

The 2022 Credit Agreement also provides the Borrowers with the right to (a) incur up to \$120,000 of additional indebtedness from third-party lenders secured by real estate excluded as collateral under the 2022 Credit Agreement, (b) incur additional mortgage financing from third-party lenders secured by real estate acquired after the closing date, and (c) upon the SAFE Banking Act or similar legislation making banking services available to U.S. cannabis companies being passed by the United States Congress, incur up to \$50,000 pursuant to a revolving credit facility from third-party lenders that is pari passu or subordinated to the 2022 Credit Agreement obligations, each of which are subject to customary conditions.

The obligations under the 2022 Credit Agreement are secured by substantially all of the assets of the Borrowers, excluding vehicles, specified parcels of real estate and other customary exclusions.

The 2022 Credit Agreement provides for a floating annual interest rate equal to the prime rate then in effect plus 6.50%, which rate may be increased by 3.00% upon an event of default that is not a material event of default or 6.00% upon a material event of default.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

7. **DEBT** (Continued)

At any time, the Company may voluntarily prepay up to \$100,000 of the principal balance, subject to a one-time \$1,000 prepayment premium upon the first prepayment, and may prepay the remaining outstanding principal balance for a prepayment premium at varying rates based on the timing of any subsequent prepayments. The Borrowers may not voluntarily prepay more than \$100,000 of the principal balance without prepaying the entire outstanding principal balance of the loan.

The 2022 Credit Agreement includes customary representations and warranties and customary events of default, including, without limitation, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to material indebtedness, and events of bankruptcy and insolvency.

The 2022 Credit Agreement also includes customary negative covenants limiting the Borrowers' ability to incur additional indebtedness and grant liens that are not otherwise permitted, and the ability to enter into or consummate acquisitions or dispositions that are not otherwise permitted, among others. Additionally, the 2022 Credit Agreement requires the Borrowers to meet certain financial tests regarding minimum cash balances, minimum levels of Adjusted EBITDA (as defined in the 2022 Credit Agreement) and a minimum fixed charge coverage ratio.

As of June 30, 2024, the Company was in compliance with such covenants.

Permitted Partial Optional Prepayment and Lien Release

On April 30, 2024, the Company, made a Permitted Partial Optional Prepayment (as defined in the 2022 Credit Agreement) in the amount of \$50,000 pursuant to the 2022 Credit Agreement and paid \$1,000 prepayment premium in connection therewith.

In connection with such Permitted Partial Optional Prepayment, Chicago Atlantic and certain Lenders agreed to (a) release certain Borrowers from their obligations under, and as parties to, the 2022 Credit Agreement and related agreements (the "Released Borrowers") and (b) release all liens over the Released Borrowers' property, including real estate, held by Chicago Atlantic for the benefit of the Lenders, in each case, pursuant to a limited consent and waiver, dated as of April 29, 2024, by and among the Borrowers, certain of the Lenders party thereto and Chicago Atlantic.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

8. SHARE CAPITAL

Subordinate Voting Shares and Proportionate Voting Shares are classified as equity. Incremental costs directly attributable to the issuance of shares are recognized as a deduction from equity. The proceeds from the exercise of stock options or warrants together with amounts previously recorded in reserves over the vesting periods are recorded as share capital. Income tax relating to transaction costs of an equity transaction is accounted for in accordance with ASC 740, *Income Taxes*.

(a) Issued and Outstanding

As of June 30, 2024, the Company had 346,417,144 Subordinate Voting Shares issued and outstanding and no Proportionate Voting Shares outstanding. The Company has the following two classes of share capital, with each class having no par value:

(i) Subordinate Voting Shares

The holders of the Subordinate Voting Shares are entitled to receive dividends issued by the Company and one vote per share at shareholder meetings of the Company. All Subordinate Voting Shares are ranked equally regarding the Company's residual assets. The Company is authorized to issue an unlimited number of Subordinate Voting Shares.

(ii) Proportionate Voting Shares

Each Proportionate Voting Share is convertible into 100 Subordinate Voting Shares. The holders of the Proportionate Voting Share are entitled to receive dividends issued by the Company on an as converted to Subordinate Voting Share basis and 100 votes per share at shareholder meetings of the Company. The Proportionate Voting Shares are ranked equally on an as converted to Subordinate Voting Share basis regarding the Company's residual assets. The Company is authorized to issue an unlimited number of Proportionate Voting Shares.

(b) Stock-Based Compensation

In February 2021, the Company established the Verano Holdings Corp. Stock and Incentive Plan (the "Plan"), which provides for stock-based remuneration for its eligible directors, officers, employees, consultants, and advisors. The maximum number of restricted stock units ("RSUs"), options and other stock based awards that may be issued under the Plan cannot exceed 10% of the Company's then issued and outstanding share capital, determined on an as converted to Subordinate Voting Shares basis. All goods and services received in exchange for the grant of any stock-based payments are measured at their fair value unless the fair value cannot be estimated reliably. If the Company cannot reliably estimate the fair value of the goods and services received, the Company measures their value indirectly by reference to the fair value of the equity instruments granted. Equity-settled stock-based payments under stock-based payment plans are ultimately recognized as an expense in profit or loss with a corresponding credit to equity.

The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. Estimates are subsequently revised if there is any indication that the number of shares expected to vest differs from the previous estimate. Any cumulative adjustment prior to vesting is recognized in the current period with no adjustment to prior periods for expense previously recognized.

Option and RSU grants generally vest in installments over 12 to 30 months and options typically have a life of ten years.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

8. SHARE CAPITAL (Continued)

Options

The Company had 36,829 fully vested and exercisable options, entitling the holder thereof to one Subordinate Voting Share per each option upon exercise, with a weighted average exercise price of C\$30.09 and a weighted average remaining contractual life of 6.02 years as of June 30, 2024.

2,127 fully vested options, entitling the holder thereof to one Subordinate Voting Share per each option upon exercise, were cancelled during the six months ended June 30, 2024 due to termination of employment. No options were granted or forfeited during the six months ended June 30, 2024. As of June 30, 2024 and December 31, 2023, there were no in-the-money options.

RSUs

The following table summarizes the number of unvested RSU awards as of June 30, 2024 and December 31, 2023 and the changes during the six months ended June 30, 2024:

	Number of Shares	Weighted Avg. Grant Date Fair Value C\$
Unvested RSUs at December 31, 2023	8,812,537	4.72
Granted	2,536,416	5.70
Forfeited	301,652	4.53
Vested	2,382,781	5.44
Unvested RSUs at June 30, 2024	8,664,520	4.83

The stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 were as follows:

	Three Months Ended June 30,					Six Months Ended June 30,			
20		2024		2023 2024			2023		
Stock Options	\$		\$	87	\$		\$	163	
Restricted Stock Units		4,316		3,661		8,244		4,129	
Total Stock Based Compensation Expense	\$	4,316	\$	3,748	\$	8,244	\$	4,292	

(c) Share Repurchase Program

On June 17, 2024, the Company's Board of Directors authorized the repurchase of up to 5%, or 17,320,857 of its Subordinate Voting Shares over a 12-month period, and in no event repurchasing greater than an aggregate cost of \$50,000. During the six months ended June 30, 2024, the Company repurchased zero Subordinate Voting Shares. The total remaining repurchase authorization remains at \$50,000.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

9. INCOME TAXES

The following table summarizes the Company's income tax expense and effective tax rates for the three and six months ended June 30, 2024 and 2023:

	Three Month	s Ended	l June 30,		Six Months Ended June 30,				
	 2024 2023 2024				2024	2023			
Income before Income Taxes	\$ 8,766	\$	14,618	\$	15,421	\$	33,701		
Income Tax Expense	(30,530)		(27,679)		(42,007)		(55,999)		
Effective Tax Rate	348 %	ó	189 %	, D	272 %))	166 %		

The effective tax rates for the three and six months ended June 30, 2024 and 2023 were based on the Company's forecasted annualized effective tax rates and were adjusted for discrete items that occurred within the periods presented. Net discrete tax items of \$8,932 and \$7,340 were recorded during the three months ended June 30, 2024 and 2023, respectively. Net discrete tax items of \$8,696 and \$12,187 were recorded during the six months ended June 30, 2024 and 2023, respectively. Discrete items recorded during the three and six months ended June 30, 2024 and 2023 primarily relate to penalties and interest on unpaid tax liabilities, impacts of prior period return to provision adjustments, remeasurement of deferred taxes for state tax rate changes, and book remeasurement adjustments not recognized for tax purposes.

Due to its cannabis operations, the Company is subject to the limitations of the U.S. Internal Revenue Code of 1986, as amended (the "Code") Section 280E, under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under Section 280E of the Code. Therefore, the effective tax rate can be highly variable and may not necessarily correlate with pre-tax income and the Company's effective tax rates are well in excess of statutory tax rates.

Taxes paid during the six months ended June 30, 2024 and 2023 were \$53,515 and \$51,706, respectively.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

10. LEASES

The Company has operating leases for some of its retail dispensaries and processing and production facilities located throughout the U.S., as well as for its corporate offices located in Chicago, Illinois. Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date.

Leases with an initial term of 12 months or less are not recorded on the Company's balance sheet. Certain leases require payments for taxes, insurance, and maintenance, and are considered non-lease components. The Company accounts for non-lease components separately.

The Company determines if an arrangement is a lease at inception. The Company must consider whether the contract conveys the right to control the use of an identified asset.

The Company leases certain business facilities from third parties under non-cancellable operating lease agreements that contain minimum rental provisions that expire through 2037. Some leases also contain renewal provisions and provide for rent abatement and escalating payments.

During the three months ended June 30, 2024 and 2023, the Company recorded approximately \$4,913 and \$4,447 in operating lease expense, respectively, of which \$114 and \$165 was included in cost of goods sold for the same periods, respectively. During the six months ended June 30, 2024 and 2023, the Company recorded approximately \$9,912 and \$8,760 in operating lease expense, respectively, of which \$228 and \$371 was included in cost of goods sold for the same periods, respectively.

Other information related to operating leases as of and for the periods ended June 30, 2024 and December 31, 2023, were as follows:

Weighted average remaining lease term - years Weighted average discount rate	June 30, 2024	December 31, 2023
Weighted average remaining lease term - years	8.10	8.19
Weighted average discount rate	9.79 %	9.52 %

Maturities of lease liabilities for operating leases as of June 30, 2024 were as follows:

Year Ending De	cember 31,	Maturities of Lease Liability
2024 (Remaining) \$	9,521
	2025	18,550
	2026	17,560
	2027	16,900
	2028	16,297
	Thereafter	66,093
Total Lease	Payments	144,921
Less: Impu	ited Interest	(47,936)
Present Value of Leas	se Liability <u>\$</u>	96,985

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

11. CONTINGENCIES AND OTHER

(a) Claims and Litigation

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of June 30, 2024, other than as set forth below, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company's consolidated operations. There are no proceedings in which the Company is a party and any of the Company's directors, officers or affiliates is an adverse party or has a material interest adverse to the Company's interest.

On January 31, 2022, the Company entered into an Arrangement Agreement (the "GGH Arrangement Agreement") with Goodness Growth Holdings, Inc. ("GGH"), pursuant to which it agreed to acquire all of the issued and outstanding equity interests of GGH in exchange for equity interests in the Company, subject to the conditions set forth in the GGH Arrangement Agreement. On October 13, 2022, the Company provided written notice to GGH of GGH's breach of the GGH Arrangement Agreement and exercised the Company's termination rights under the GGH Arrangement Agreement. On October 21, 2022, GGH filed suit against the Company in the Supreme Court of British Columbia alleging that the Company breached (i) the GGH Arrangement Agreement through, among other things, the purported wrongful repudiation of the GGH Arrangement Agreement, (ii) the duty of good faith, and (iii) the duty of honest performance in contract. In addition, on November 14, 2022, the Company filed a counterclaim asserting that GGH owes it a termination fee in the amount of \$14,875, or alternatively, the reimbursement of out-of-pocket fees and expenses of up to \$3,000 as a result of our termination of the GGH Arrangement Agreement, which was based upon our belief that GGH breached covenants and representations in the GGH Arrangement Agreement and the occurrence of other termination events. GGH filed a response to such counterclaim on December 7, 2022, in which GGH denied it was obligated to pay any termination fee or transaction expenses. As of June 30, 2024, both the Company and GGH are engaged in ongoing discovery efforts.

On May 2, 2024, GGH filed an application with the Supreme Court of British Columbia seeking an order granting summary trial in the ongoing litigation between the Company and GGH regarding the GGH Arrangement Agreement. In the application, GGH stated it is seeking \$860,900 in damages, plus costs and interest (the "GGH Application for Summary Trial"). On June 19, 2024, the Company filed an application in response seeking: (i) dismissal of the GGH Application for Summary Trial on the grounds that the issues raised by it are not suitable for disposition by summary trial and will not assist the efficient resolution of the proceeding; and (ii) an order that the report on damages filed by GGH in support of the GGH Application for Summary Trial is inadmissible and shall be excluded from evidence in the trial, or any summary trial, of this matter. The Company can provide no guarantees or assurances that it will prevail or settle this lawsuit or its counterclaim on favorable terms, if at all, and an adverse outcome could have a material adverse effect on its business, results of operations and financial condition.

(b) Contingencies

During the first quarter of 2023, the Company discovered a potential liability related to a previous acquisition that was deemed to be both probable and estimable. Per ASC 450 *Contingencies*, when both of these criteria are present, a contingent liability should be recorded. Based on this, the Company recorded a corresponding charge in Other Income, net of \$1,893 for the six months ended June 30, 2023.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

11. CONTINGENCIES AND OTHER (Continued)

(c) Illegality of Cannabis at the U.S. Federal Level

Verano operates within states where cannabis use, medical or adult-use or both, has been approved by state and local regulatory bodies. Notwithstanding the permissive regulatory environment of medical, and in some cases also adult-use cannabis at the state level, under U.S. federal law cannabis (other than hemp) is a Schedule I controlled substance under the Controlled Substances Act (21 U.S.C. § 811) (the "Controlled Substances Act") which means it is viewed by the U.S. federal government as a drug that has a high potential for abuse and no therapeutic value. Therefore, even in states or territories that have legalized cannabis to some extent, the cultivation, processing, distribution, possession and sale of cannabis violates the Controlled Substances Act. Moreover, individuals and entities may violate U.S. federal law if they aid and abet another in violating the Controlled Substances Act or conspire with another to violate the law. Violating the Controlled Substances Act is also a predicate for other crimes, including money laundering laws and the Racketeer Influenced and Corrupt Organizations Act. Violations of any U.S. federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, disgorgement of profits, cessation of business activities, civil forfeiture or divestiture.

Strict compliance with state and local laws with respect to cannabis may neither absolve the Company of liability under U.S. federal law, nor may it provide a defense to any federal proceeding which may be brought against the Company. This could have a material adverse effect on the Company, including its reputation and ability to conduct business, its cannabis licenses in the U.S., the listing and trading of its securities on stock exchanges and platforms, its financial position, operating results, profitability, liquidity and the market price of its publicly traded shares. In addition, it is difficult for the Company to estimate the time or resources that would be needed for the investigation of any such matters or its final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time and resources could be substantial.

There can be no assurance that the comprehensive U.S. federal legislation that would de-schedule and de-criminalize cannabis will be passed in the near future or at all. If such legislation is passed, there is no guarantee that it will include provisions that preserve the current state-based cannabis programs under which the Company operates or that such legislation will otherwise be favorable to the Company and its business.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

12. SEGMENTS

The Company conducts and manages its business through two reportable segments, representing the major lines of its cannabis business: cultivation (wholesale) and retail. The cultivation (wholesale) segment consists of the cultivation, production and sale of cannabis products to retail stores. The retail segment consists of the retailing of cannabis to patients and consumers. Summarized financial information for these segments is as follows:

	,	Three Months Ended June 30,			Six Months Ended June 30,			
		2024		2023		2024		2023
Revenues, net of Discounts								
Cultivation (Wholesale)	\$	92,473	\$	86,610	\$	178,379	\$	166,877
Retail		164,683		186,358		333,271		370,600
Intersegment Eliminations		(34,766)		(38,853)		(67,954)		(76,302)
Total Revenues, net of Discounts		222,390		234,115		443,696		461,175
Gross Profit								
Cultivation (Wholesale)		28,030		12,745		52,216		23,569
Retail		86,310		102,446		175,084		200,807
Total Gross Profit		114,340		115,191		227,300		224,376
Depreciation and Amortization								
Cultivation (Wholesale)		19,194		18,529		38,282		37,050
Retail		16,539		16,708		33,003		33,243
Total Depreciation and Amortization		35,733		35,237		71,285		70,293
Income taxes								
Cultivation (Wholesale)		8,592		8,754		14,499		19,011
Retail		21,938		18,925		27,508		36,988
Total Income Taxes		30,530		27,679		42,007		55,999

The following table reconciles gross profit to consolidated income before provision for income taxes.

	Three Months Ended June 30,				Six Months Ended June 30,			
		2024		2023		2024		2023
Gross Profit	\$	114,340	\$	115,191	\$	227,300	\$	224,376
Selling, General, and Administrative Expenses		(87,074)		(84,660)		(177,363)		(159,908)
Loss from Investments in Associates		_		(101)		_		(261)
Total Other Income (Expense), net		(18,500)		(15,812)		(34,516)		(30,506)
Income Before Provision for Income Taxes		8,766		14,618		15,421		33,701

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

13. LOYALTY OBLIGATIONS

The Company has customer loyalty programs where retail customers accumulate points for each dollar of spending, net of tax. These points are recorded as a contractual liability until customers redeem their points for discounts on eligible products as part of an in-store sales transaction. In addition, the Company records a performance obligation as a reduction of revenue based on the estimated probability of point obligation incurred.

The Company has a calculated standalone selling price that ranges between \$0.03\cdot and \$0.06\cdot per loyalty point. Upon redemption, the loyalty program obligation is relieved, and the offset is recorded as revenue. The Company estimates that 20% of points will not be redeemed (breakage) prior to their six-month expiration dates. The Company continues to evaluate breakage and redemption values to determine the standalone selling price.

As of December 31, 2023, there were approximately 110,000,000¹ points outstanding with an approximate value of \$5,781. As of June 30, 2024, there were approximately 83,000,000¹ points outstanding with an approximate value of \$4,250. During the three months ended June 30, 2024, the Florida market transitioned to a new loyalty rewards program. The points associated with the prior rewards program were transitioned to store credits which approximated the value attributable to the respective outstanding loyalty points. Such balances are included in accrued liabilities on the Company's Condensed Consolidated Balance Sheets.

¹ Such amount not in Thousands

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

14. CONSOLIDATION

In accordance with ASC 810, the Company consolidates through the variable interest entity ("VIE") model. The following table presents the summarized financial information about the Company's consolidated VIEs, which are included in the Company's Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023.

	J	une 30, 2024	ember 31, 2023
Current Assets	\$	5,961	\$ 14,671
Non-Current Assets		26,272	28,568
Current Liabilities		28,152	30,437
Non-Current Liabilities		6,194	7,614
Equity attributable to Verano Holdings Corp.		(2,113)	5,188

Consolidated Variable Interest Entities

Consolidated VIEs occur when (a) the Company closes an acquisition while the state has not finalized the transfer of the cannabis license or (b) the Company owns an equity interest in a joint venture, which it exercises control over.

Consolidation occurs on the effective date of the purchase agreement, or in the case of joint venture VIEs, on the effective date of a limited liability company agreement governing the applicable joint venture, and an MSA. The MSA grants the management company, Verano, the ability to make business operating decisions, manage and staff employees, determine product mix, and the authority to direct allocation of cash. The MSA or the limited liability company agreement also allows Verano to limit distributions of the entity at Verano's discretion. Certain states may limit the distribution or transfer of cash until license transfer.

The Company has entered into financing arrangements with certain VIEs to provide funding for potential capital expenditures including, but not limited to, the construction of dispensaries and other facilities.

The Company applies ASC 810-10-15 to determine control of the legal entity. With respect to VIEs acquired via acquisition, the purchase agreements limit the sellers involvement in future operations, and their risks of loss. With respect to joint venture VIEs, the limited liability company agreements limit the partners' involvement in future operations and control over financial decisions, including distributions. In addition, Verano enters into an MSA with the legal entity that grants the Company strategic decision-making ability of the business operations.

The Company is involved in all qualitative and quantitative aspects of each consolidated VIE, such as but not limited to, software choices, procurement, staffing and payroll, advertising, and use of cash flow. With respect to VIEs acquired via acquisition, the Company absorbs all risk of loss and receives expected future returns based on the purchase agreement and MSA, resulting in Verano being the primary beneficiary.

Verano does not fully own all entities consolidated under ASC 810 and records a non-controlling interest for such non-owned portion in the Unaudited Interim Condensed Consolidated Financial Statements. The income of less-than-wholly owned entities is attributed to non-controlling interest and Verano based on the contractual arrangements between the other interest holders and Verano, or, in the absence of contractual arrangements, on a pro rata basis based on relative ownership percentage. As an exception to the aforementioned attribution method, during periods in which a less-than-wholly owned entity records an accumulated deficit, the net losses of the less-than-wholly owned subsidiary are, generally, attributed entirely to Verano.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

15. FAIR VALUE MEASUREMENTS

The Company applies fair value accounting for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers all related factors of the asset by market participants in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions, and credit-risk.

The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels, and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

- Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and
- Level 3 Inputs for the asset or liability that are not based on observable market data.

Financial Instruments

The Company's financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, debt, and acquisition consideration payable.

For the Company's long-term debt (which primarily consists of a credit facility and mortgage loans), for which there were no quoted market prices of active trading markets, it was not practicable to estimate the fair value of these financial instruments. The carrying amount of debt as of June 30, 2024 and December 31, 2023 was \$395,778 and \$445,642, which included \$4,055 and \$52,005, respectively, of short-term debt due within one year.

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of the inputs to fair value measurements. The fair value of the Company's financial instruments associated with each of the three levels of the hierarchy are:

			As of Jun	e 30	, 2024	
		Level 1	Level 2		Level 3	Total
Cash and Cash Equivalents	\$	130,052	\$ _	\$		\$ 130,052
Investments		2,460	_		_	2,460
Acquisition Consideration Payable		_	_		(4,106)	(4,106)
Total	\$	132,512	\$ 	\$	(4,106)	\$ 128,406
	==					
			As of Decem	ber	31, 2023	
		Level 1	Level 2		Level 3	Total
Cash and Cash Equivalents	\$	174,760	\$ 	\$		\$ 174,760
Investments		2,294	_			2,294
Acquisition Consideration Payable		_	_		(3,915)	(3,915)
Total	\$	177,054	\$ _	\$	(3,915)	\$ 173,139

As of June 30, 2024, the Company held publicly traded shares of \$2,460, which is included in other assets in the accompanying Condensed Consolidated Balance Sheet, and is a Level 1 financial instrument.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

16. RELATED PARTY TRANSACTIONS

2022 Credit Agreement

George Archos, the Chairman, Chief Executive Officer and Founder of the Company, participated in the 2022 Credit Agreement as a Lender funding \$1,000 of the \$350,000 principal amount. Mr. Archos is excluded from certain approval rights of the lenders and any penalties and fees due to Mr. Archos under the 2022 Credit Agreement are immaterial to the Company.

Two Pointo

In October 2022, the Company entered into a conditional management and services agreements with each of Americana Dream, LLC and Green Therapy, LLC, operators of dispensaries in Illinois pursuant to social equity licenses issued by Illinois regulatory authorities (together, the "LLCs"), and in 2023 the Company received an aggregate of \$10 for services rendered under the agreements. The Company sold products to the LLCs and two associated entities on a wholesale basis in the aggregate amounts of \$1,321 and \$632, net of discounts, for the three months ended June 30, 2024 and 2023, respectively. The Company sold products to the LLCs and two associated entities on a wholesale basis in the aggregate amounts of \$2,175 and \$1,056, net of discounts, for the six months ended June 30, 2024 and 2023, respectively. Two Pointo, LLC ("Two Point") has contractual rights to purchase ownership interests in the LLCs and associated entities, subject to submitting a request for and receiving applicable Illinois regulatory approvals and other conditions. The existing owners of the LLCs and associated entities will maintain ownership interests together with Two Point. In 2023, Darren Weiss, the Company's President, received in connection with application support services rendered to an LLC in 2019, (i) a 2.73% profit interest in Two Point subject to Two Point's purchase of ownership interests in the LLCs, and (ii) a profit interest in Two Point of 0.30%, and David Spreckman, the Company's Chief Marketing Officer, received a profit interest in Two Point of 0.30% for services. All profit interests issued to Messrs. Weiss and Spreckman were voluntarily forfeited in 2024 as if they were never granted. Maria Fragias, an immediate family member of George Archos, the Company's Chief Executive Officer, is the beneficiary of a trust that holds a 7.92% ownership interest and a 3.95% profit interest in Two Point. To the Company's knowledge, none of the trust or such persons has received any distributions, payments, or proceeds from Two Point.

Leases

The Company leases real property for a retail dispensary in Aurora, Illinois from 740 Rte. 59, LLC ("740"). Pursuant to the lease agreement, the Company made payments totaling \$46 and \$46 during each of the three months ended June 30, 2024 and 2023, respectively, and \$92 and \$92 during each of the six months ended June 30, 2024 and 2023, respectively. Payments consist of base rent, real estate taxes and customary tenant charges. George Archos, the Company's Chief Executive Officer, holds an indirect 50% ownership interest in 740. Pursuant to the lease agreement, the initial term expires on June 30, 2030.

The Company leases real property for a retail dispensary in Lombard, Illinois from 783 Butterfield LLC ("783"). Pursuant to the lease agreement, the Company made payments to 783 totaling \$91 and \$90 during the three months ended June 30, 2024 and 2023, respectively, and \$182 and \$180 during the six months ended June 30, 2024 and 2023, respectively. Payments consist of base rent, real estate taxes and customary tenant charges. George Archos, the Company's Chief Executive Officer, holds a 50% indirect ownership interest in 783. Pursuant to the lease agreement, the initial term expires on January 11, 2031.

Sweed

High Tech Holdings, Inc. ("Sweed") provides point of sale software systems to retail cannabis businesses under the names "Sweed" and "Leaftrade." Sweed provides these software systems to the Company. For these services the Company paid Sweed \$674 during the year ended December 31, 2023 and \$643 during the six months ended June 30, 2024. GP Management Group, LLC, an entity beneficially owned and controlled by George Archos, holds a 0.476% ownership interest in Sweed.

Notes to Unaudited Interim Condensed Consolidated Financial Statements

(\$ in Thousands except shares and per share amounts)

17. SUBSEQUENT EVENTS

Entry into a Material Definitive Agreement

On July 29, 2024, the Company entered into (i) an equity purchase agreement to acquire all of the issued and outstanding equity interests of 203 Organix, L.L.C., an Arizona limited liability company ("203 Organix), for a purchase price, subject to adjustment, of \$9,900 of cash proceeds, (ii) an equity purchase agreement to acquire all of the issued and outstanding equity interests of Salubrious Wellness Clinic, Inc., an Arizona limited liability company ("SWC"), for a purchase price, subject to adjustment, of \$5,100 of cash proceeds, and (iii) an equity purchase agreement to acquire all of the issued and outstanding equity interests of Columbia Care Eastern Virginia LLC, a Virginia limited liability company ("CC EV"), for an aggregate purchase price, subject to adjustment, of \$90,000, consisting of \$20,000 of cash proceeds, \$30,000 issued pursuant to a two-year promissory note bearing interest at 7% per annum and \$40,000 of Subordinate Voting Shares (such equity purchase agreements collectively, the "Transactions"). Closing under each of the Transactions is subject to closing conditions, including approval of applicable regulatory bodies.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management discussion and analysis (this "MD&A") of the financial condition and results of operations of the Company is for the three and six months ended June 30, 2024 and June 30, 2023. It is supplemental to, and should be read in conjunction with, the Company's Unaudited Interim Condensed Consolidated Financial Statements and the accompanying notes for the three and six months ended June 30, 2024 and with the Company's 2023 Annual Audited Financials for the years ended December 31, 2023, 2022 and 2021 included in the Form 10-K. The financial statements referenced in this MD&A are prepared in accordance with GAAP. Financial information presented in this MD&A is presented in United States dollars ("\$" or "US\$") and expressed in thousands, unless otherwise indicated. This MD&A contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those projected, forecasted, or expected in these forward-looking statements as a result of various factors, including, but not limited to, those discussed in the Form 10-K. See "Cautionary Statement Regarding Forward-Looking Statements" above and "Risk Factors" in Part I, Item 1A. "Risk Factors" in the Form 10-K. The Company's management believes the assumptions underlying the Company's financial statements and accompanying notes are reasonable. However, the Company's financial statements and accompanying notes may not be an indication of the Company's financial condition and results of operations in the future.

OVERVIEW OF THE COMPANY

Verano, one of the U.S. cannabis industry's leading companies based on historical revenue, geographical scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying *Yes* to plant progress and the bold exploration of cannabis. An operator of licensed cannabis cultivation, processing, wholesale distribution and retail facilities, our goal is the ongoing development of communal wellness by providing responsible access to regulated medical and adult-use cannabis products to discerning customers. As of August 5, 2024 through our subsidiaries and affiliates we operate businesses in 13 states, including 142 retail dispensaries and 13 production facilities with over 1,000,000 square feet of cultivation capacity, not including any facilities that may be acquired pursuant to the Transactions. We produce a wide variety of high quality cannabis products sold under our portfolio of consumer brands, including EncoreTM, AvexiaTM, MÜVTM, SavvyTM, BITSTM and VeranoTM. We also design, build and operate branded retail environments including Zen LeafTM and MÜVTM dispensaries that deliver a cannabis shopping experience in both medical and adult-use markets, including through Cabbage Club, an annual membership program offering exclusive benefits for cannabis consumers.

Notwithstanding the permissive regulatory environment of medical, and in some cases, also adult-use (i.e., recreational) cannabis, at the state level, it remains illegal under U.S. federal law to cultivate, manufacture, distribute, sell or possess cannabis in the U.S. Because federal law prohibits transporting any federally restricted substance across state lines, cannabis cannot be transported across state lines. As a result of current federal law prohibitions, the U.S. cannabis industry is conducted on a state-by-state basis. To date, in the U.S. 38 states plus the District of Columbia and the U.S. territories of Puerto Rico, Guam, the Commonwealth of Northern Marina Islands, and the U.S. Virgin Islands have authorized comprehensive medical cannabis programs, 24 states plus the District of Columbia and the U.S. territories of Guam, the Commonwealth of Northern Mariana Islands, and the U.S. Virgin Islands have authorized comprehensive programs for medical and adult-use (i.e. recreational) cannabis, and 7 states allow the use of low tetrahydrocannabinol and high cannabidiol products for specified medical uses. Verano operates within states where cannabis use, medical or both medical and adult-use, has been approved by state and local regulatory bodies. Strict compliance with state and local laws with respect to cannabis may neither absolve the Company of liability under U.S. federal law, nor may it provide a defense to any federal proceeding which may be brought against the Company or any of its subsidiaries.

Our strategy is to vertically integrate as a single cohesive company in multiple states through the consolidation of seed-to-sale cultivating, manufacturing, distributing, and dispensing cannabis brands and products at scale. Our cultivation, processing and wholesale distribution of cannabis consumer packaged goods are designed to support our national retail dispensary chains, and to develop and foster long-term wholesale supply relationships with third-party retail dispensary operators. Our strategy includes geographic diversity by establishing a footprint to enable us to adapt to changes in both industry and market conditions.

SELECTED RESULTS OF OPERATIONS

The following presents selected financial data derived from the (i) Unaudited Interim Condensed Consolidated Financial Statements for the three and six months ended June 30, 2024 and 2023 and (ii) the Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023, and should be read in conjunction with the Unaudited Interim Condensed Consolidated Financial Statements and accompanying notes presented in Item 1 of this Form 10-Q. The selected Unaudited Interim Condensed Consolidated financial information below may not be indicative of the Company's future performance.

Three Months Ended June 30, 2024, as Compared to Three Months Ended June 30, 2023

	For the Three Months Ended June 30,			
(\$ in thousands)		2024	2023	\$ Change
Revenues, net of discounts	\$	222,390 \$	234,115	\$ (11,725)
Gross Profit		114,340	115,191	(851)
Net Loss attributable to Verano Holdings Corp. & Subsidiaries		(21,764)	(13,061)	(8,703)
Net Loss per share – basic & diluted		(0.06)	(0.04)	(0.02)

Revenues, net of discounts

Revenues, net of discounts, for the three months ended June 30, 2024 was \$222,390, a decrease of \$(11,725) or (5.0)%, compared to revenue of \$234,115 for the three months ended June 30, 2023. The decrease in revenue was driven primarily by expected declines in New Jersey retail as dispensaries continue to open across the state partially offset by increases in Maryland retail and wholesale in relation to the adult-use program launch in July 2023, and new Zen LeafTM store openings in the Connecticut market during the third and fourth quarters of 2023. During the three months ended June 30, 2024, the Company opened four new stores, three in Florida and one in Connecticut. Additionally, consistent with other multi-state cannabis operators, the Company has seen increased competition and promotional activity in select retail markets, specifically in New Jersey and Illinois. Retail revenue for the three months ended June 30, 2024 was approximately 64.0% of total revenue compared to 68.3% of total revenue for the three months ended June 30, 2023, in each case, excluding intersegment eliminations. Cultivation (wholesale) revenues increased due to increased third-party wholesale sales, mainly in the New Jersey and Maryland markets, due to growing wholesale accounts and a burgeoning adult-use program, respectively, when compared to the three months ended June 30, 2023. Cultivation (wholesale) revenue for the three months ended June 30, 2024 was 36.0% of total revenue compared to 31.7% of total revenue for the three months ended June 30, 2023, in each case, excluding intersegment eliminations.

Gross Profit

Gross profit for the three months ended June 30, 2024 was \$114,340, representing a gross margin on the sale of cannabis, cannabis extractions, edibles and related accessories of 51.4%. This is compared to gross profit for the three months ended June 30, 2023 of \$115,191, which represented a 49.2% gross margin on the sale of cannabis, cannabis extractions, edibles and related accessories. The decrease in gross profit during the three months ended June 30, 2024 compared to the three months ended June 30, 2023, was due to increased competition and modest pricing pressure in the retail markets partially offset by higher third-party wholesale sales of Verano products.

Net Loss

Net Loss attributable to the Company for the three months ended June 30, 2024 was \$(21,764), an increase of \$8,703, compared to a net loss of \$(13,061) for the three months ended June 30, 2023. The increase in net loss was driven by a loss on debt extinguishment attributable to the Permitted Partial Optional Prepayment under the 2022 Credit Agreement and a slight increase in selling, general and administrative expenses ("SG&A") for the three months ended June 30, 2024 compared to the three months ended June 30, 2023. The change in net loss was also a result of increased provision for income taxes for the three months ended June 30, 2024 compared to the three months ended June 30, 2023.

For the	Three Months	Ended J	lune 30,
2024	2022		0.01

(\$ in thousands)	 2024	2023		\$ Change	
Cost of Goods Sold, net	\$ 108,050 \$	118,924	\$	(10,874)	
Selling, General, and Administrative Expenses	87,074	84,660		2,414	
Other Income (Expense), net	(18,500)	(15,812)		(2,688)	
Provision for Income Taxes	(30,530)	(27,679)		(2,851)	

Cost of Goods Sold, net

Cost of goods sold, net includes the costs directly attributable to cultivating and processing cannabis and for retail purchases of finished goods, such as flower, edibles, and concentrates. Cost of goods sold, net for the three months ended June 30, 2024 was \$108,050, a decrease of \$(10,874) or (9.1)%, as compared to the three months ended June 30, 2023. The decrease was attributable to lower top-line revenue due to increased competition and modest pricing pressure in select retail markets, partially offset by increased third-party wholesale sales of Verano products.

Selling, General, and Administrative Expenses

Selling, general and administrative expenses for the three months ended June 30, 2024 were \$87,074, an increase of \$2,414 or 2.9%, compared to SG&A expenses of \$84,660 for the three months ended June 30, 2023. SG&A expenses as a percentage of revenue was 39.2% and 36.2% for the three months ended June 30, 2024, and June 30, 2023, respectively. The increase was primarily due to a \$2,858 increase in salaries and benefits, due to increased headcounts related to new store openings during the three months ended June 30, 2024 compared to the three months ended June 30, 2023.

Other Income (Expense), net

Other income (expense), net for the three months ended June 30, 2024, was \$(18,500), an increase of \$2,688 as compared to the three months ended June 30, 2023. The other income (expense), net increase was mainly due to a loss on debt extinguishment attributable to the Permitted Partial Optional Prepayment under the 2022 Credit Agreement.

Provision for Income Taxes

Income tax expense is recognized based on the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at year-end. Income tax expense for the three months ended June 30, 2024, was \$30,530, an increase of \$2,851 or 10.3% when compared to the three months ended June 30, 2023.

Six Months Ended June 30, 2024, as Compared to Six Months Ended June 30, 2023

	For the Six Months Ended June 30,							
(\$ in thousands)		2024		2023		\$ Change		
Revenues, net of discounts	\$	443,696	\$	461,175	\$	(17,479)		
Gross Profit		227,300		224,376		2,924		
Net Loss attributable to Verano Holdings Corp. & Subsidiaries		(26,586)		(22,298)		(4,288)		
Net Loss per share – basic & diluted		(0.08)		(0.07)		(0.01)		

Revenues, net of discounts

Revenues, net of discounts, for the six months ended June 30, 2024 was \$443,696, a decrease of \$(17,479) or (3.8)%, compared to revenue of \$461,175 for the six months ended June 30, 2023. The decrease in revenue was driven primarily by expected declines in New Jersey retail as dispensaries continue to open across the state partially offset by increases in Maryland retail and wholesale in relation to the adult-use program launch in July 2023, and new Zen LeafTM store openings in the Connecticut market during the third and fourth quarters of 2023. During the six months ended June 30, 2024, the Company opened six new stores, one in Connecticut, four in Florida and one in Pennsylvania. Additionally, consistent with other multi-state cannabis operators, the Company has seen increased competition and promotional activity in select retail markets, specifically in New Jersey and Illinois. Retail revenue for the six months ended June 30, 2024 was approximately 65.1% of total revenue compared to 69.0% of total revenue for the six months ended June 30, 2023, in each case, excluding intersegment eliminations. Increased cultivation (wholesale) revenues were driven by third-party wholesale sales in the New Jersey market and increased adult-use third-party wholesale sales in the Maryland market, both, of which attributed to increased production output and sales of cannabis flower and cannabis related products when compared to the three months ended June 30, 2023. Cultivation (wholesale) revenue for the six months ended June 30, 2024 was 34.9% of total revenue compared to 31.0% of total revenue for the six months ended June 30, 2023, in each case, excluding intersegment eliminations.

Gross Profit

Gross profit for the six months ended June 30, 2024 was \$227,300, representing a gross margin on the sale of cannabis, cannabis extractions, edibles and related accessories of 51.2%. This is compared to gross profit for the six months ended June 30, 2023 of \$224,376, which represented a 48.7% gross margin on the sale of cannabis, cannabis extractions, edibles and related accessories. The increase in gross profit during the six months ended June 30, 2024 was attributable to higher third-party wholesale sales of Verano products, which was partially offset by continued competition and pricing pressure in the retail markets.

Net Loss

Net loss attributable to the Company for the six months ended June 30, 2024 was \$(26,586), an increase of \$4,288, compared to a net loss of \$(22,298) for the six months ended June 30, 2023. The increase in net loss was driven by an increase in selling, general and administrative expenses and a loss on debt extinguishment attributable to the Permitted Partial Optional Prepayment under the 2022 Credit Agreement for the six months ended June 30, 2024 compared to the six months ended June 30, 2023.

For the	Six	Months	Ended	June 30.
roi inc	1712		rinaca	June 30.

(\$ in thousands)	 2024	2023	\$ Change
Cost of Goods Sold, net	\$ 216,396 \$	236,799	\$ (20,403)
Selling, General, and Administrative Expenses	177,363	159,908	17,455
Other Income (Expense), net	(34,516)	(30,506)	(4,010)
Provision for Income Taxes	(42,007)	(55,999)	13,992

Cost of Goods Sold, net

Cost of goods sold, net, includes the costs directly attributable to cultivating and processing cannabis and for retail purchases of finished goods, such as flower, edibles, and concentrates. Cost of goods sold, net, for the six months ended June 30, 2024 was \$216,396, a decrease of \$(20,403) or (8.6)%, as compared to the six months ended June 30, 2023. The decrease was primarily driven by decreased top-line revenue within the retail markets due to expected declines in New Jersey retail as dispensaries continue to open across the state, partially offset by increased wholesale sales of Verano products to third-parties in select markets, specifically in the New Jersey adult-use market.

Selling, General, and Administrative Expenses

Selling, general and administrative expenses for the six months ended June 30, 2024 were \$177,363, an increase of \$17,455 or 10.9%, compared to SG&A expenses of \$159,908 for the six months ended June 30, 2023. SG&A expenses as a percentage of revenue was 40.0% and 34.7% for the six months ended June 30, 2024, and June 30, 2023, respectively. The increase was primarily due to a \$9,263 increase in salaries and benefits due to increased headcounts, and a \$6,176 increase in general and administrative expenses primarily driven by enhancements in processes and technology, during the six months ended June 30, 2024 compared to the three months ended June 30, 2023. Additionally, SG&A expenses for the six months ended June 30, 2024 included higher stock based compensation expense compared to the six months ended June 30, 2023, driven by a prior period expense acceleration benefit during the six months ended June 30, 2023 and lower award grants during the six months ended June 30, 2023.

Other Income (Expense), net

Other income (expense), net for the six months ended June 30, 2024, was \$(34,516), a change of \$(4,010) as compared to the six months ended June 30, 2023. The other income (expense), net change was mainly due to a loss on debt extinguishment attributable to the Permitted Partial Optional Prepayment under the 2022 Credit Agreement and the Company's contributions to Florida's Smart & Safe adult-use legalization campaign.

Provision for Income Taxes

Income tax expense is recognized based on the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at year-end. Income tax expense for the six months ended June 30, 2024, was \$(42,007), a decrease of \$13,992 or 25.0% primarily due to impacts of prior period return to provision adjustments and a decrease in pre-tax earnings when compared to the six months ended June 30, 2023.

Results of Operations by Segment

The Company has two reportable segments: (i) cultivation (wholesale) and (ii) retail. Due to the vertically integrated nature of its business, the Company reviews its revenue at the cultivation (wholesale) and retail levels while reviewing its operating results on a consolidated basis.

The following tables summarize revenues, net of discounts, by segment for the three and six months ended June 30, 2024 and 2023:

For the	Thron	Mont	he En	hob	June 30.
FORTHE	Inree	viont	ns r.n	aea .	June Su.

(\$ in thousands)		2024		2023	\$ Change		% Change		
Revenues, net of discounts									
Cultivation (Wholesale)	\$	92,473	\$	86,610	\$	5,863	6.8 %		
Retail		164,683		186,358		(21,675)	(11.6)%		
Intersegment Eliminations		(34,766)		(38,853)		4,087	(10.5)%		
Total Revenues, net of discounts	\$	222,390	\$	234,115	\$	(11,725)	(5.0)%		

Revenues, net of discounts, for the cultivation (wholesale) segment were \$92,473 for the three months ended June 30, 2024, an increase of \$5,863 or 6.8%, compared to the three months ended June 30, 2023, in each case, excluding intersegment eliminations. The increase in cultivation (wholesale) revenues, net of discounts, was primarily driven by increased third party wholesale sales due to the increased third party dispensaries in the New Jersey and Illinois markets.

Revenues, net of discounts, for the retail segment were \$164,683 for the three months ended June 30, 2024, a decrease of \$(21,675) or (11.6)%, compared to the three months ended June 30, 2023, in each case, excluding intersegment eliminations. Top contributors to retail sales growth were in the Maryland and Connecticut markets due to a burgeoning adult-use market and new store openings, respectively. The decrease in retail revenues, net of discounts was primarily driven by increased competition in both the New Jersey and Illinois markets which contributed to the year over year revenue decrease.

For the Six Months Ended June 30,

(\$ in thousands)	2024 2023		\$ Change	% Change	
Revenues, net of discounts					
Cultivation (Wholesale)	\$	178,379	\$ 166,877	\$ 11,502	6.9 %
Retail		333,271	370,600	(37,329)	(10.1)%
Intersegment Eliminations		(67,954)	(76,302)	8,348	(10.9)%
Total Revenues, net of discounts	\$	443,696	\$ 461,175	\$ (17,479)	(3.8)%

Revenues, net of discounts, for the cultivation (wholesale) segment were \$178,379 for the six months ended June 30, 2024, an increase of \$11,502 or 6.9%, compared to the six months ended June 30, 2023, in each case, excluding intersegment eliminations. The increase in cultivation (wholesale) revenues, net of discounts, was primarily driven by increased third-party wholesale sales in the Illinois and New Jersey markets coupled with a burgeoning adult-use third-party wholesale sales in the Maryland market, both of which attributed to increased production output of cannabis flower and cannabis related products.

Revenues, net of discounts, for the retail segment were \$333,271 for the six months ended June 30, 2024, a decrease of \$(37,329) or (10.1)%, compared to the six months ended June 30, 2023, in each case, excluding intersegment eliminations. Top contributors to retail sales were mainly in the Maryland market, due to the adult-use program launch in July 2023 and in the Connecticut market due to new store openings in the second half of 2023. The overall decrease in retail revenues, net of discounts, was primarily driven by increased competition and promotional activity in select retail markets, specifically in New Jersey and Illinois. Additionally, modest pricing pressure contributed to the decrease in revenues, net of discounts, when comparing the six months ended June 30, 2024 to the six months ended June 30, 2023.

Drivers of Operational Performance

Revenue

The Company derives its revenue from both its cultivation (wholesale) business in which it cultivates, produces and sells cannabis products to third-party retail customers, and its retail business, in which it directly sells cannabis products to retail patients and consumers. For the three months ended June 30, 2024, approximately 36.0% of the Company's revenue was generated from the cultivation (wholesale) business, excluding intersegment eliminations, and approximately 64.0% from the retail business, excluding intersegment eliminations. For the six months ended June 30, 2024, approximately 34.9% of revenue was generated from the cultivation (wholesale) business and approximately 65.1% from the retail business, excluding intersegment eliminations.

Gross Profit

Gross profit is revenue less cost of goods sold, net. Cost of goods sold, net includes the costs directly attributable to product sales and includes amounts paid for finished goods, such as flower, edibles, and concentrates, as well as packaging and other supplies, fees for services and processing, rent, utilities, and related costs. Cannabis costs are affected by various state regulations that limits the sourcing and procurement of cannabis products, which may create fluctuations in gross profit over comparative periods as the regulatory environment changes. Gross profit margin measures the Company's gross profit as a percentage of revenue.

The Company's expansion strategy and revenue growth have taken priority and will continue to do so for the foreseeable future as it expands its footprint, by exploring new markets and opening or acquiring new dispensary locations, and scales production within current markets. In the core markets in which the Company is already operational and, as the state markets mature, the Company anticipates that there will be pressure on margins in the cultivation (wholesale) and retail channels. The Company's current production capacity has not been fully realized and it is expected that price compression at the cultivation (wholesale) level, will be offset by operational optimization. As a result, the Company expects overall consolidated gross profit margins to gradually increase in the future.

Total Expenses

Total expenses, other than the cost of goods sold, consist of selling costs to support customer relationships and to deliver product to the Company's retail stores. It also includes a significant investment in the corporate infrastructure required to support ongoing business.

Selling costs generally correlate to revenue. As a percentage of sales, selling costs are expected to increase slightly in currently operational markets (Arizona, Arkansas, Connecticut, Florida, Illinois, Maryland, Massachusetts, Michigan, Nevada, New Jersey, Ohio, Pennsylvania, and West Virginia) as facility and market expansion occurs. The increase is expected to be driven primarily by the growth of the Company's retail and cultivation (wholesale) channels and the ramp up from new retail openings.

SG&A expenses also include costs incurred at the Company's corporate offices, primarily related to back-office personnel costs, including salaries, incentive compensation, benefits, stock-based compensation and professional service costs. Going forward, SG&A expenses are expected to continue in line with the Company's expansion plans. Furthermore, the Company expects to continue to incur acquisition and transaction costs related to these expansion plans and anticipates stock compensation expenses related to recruiting and hiring talent, along with legal and professional fees associated with being a public-reporting company and publicly traded in Canada and a public-reporting company in the U.S.

Provision for Income Taxes

The Company is subject to income taxes in the jurisdictions in which it operates and, consequently, income tax expense is a function of the allocation of taxable income by jurisdiction and the various activities that impact the timing of taxable events. As the Company operates in the cannabis industry, it is subject to the limits of Section 280E of the Code under which the Company is only allowed to deduct expenses directly related to the sale of products. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under Section 280E of the Code and a higher effective tax rate than most industries.

During the second quarter of 2023, Connecticut, Illinois, and New Jersey enacted tax legislation to exempt, or decouple, from Section 280E of the Code, all of which became retroactively effective as of January 1, 2023. The Company has significant operations in these states and is now permitted to deduct ordinary and necessary cannabis business expenses in these states.

LIQUIDITY, FINANCING ACTIVITIES AND CAPITAL RESOURCES

As of June 30, 2024 and December 31, 2023, the Company had total current liabilities of \$360,591 and \$412,188, respectively. As of June 30, 2024 and December 31, 2023, the Company had cash and cash equivalents of \$130,052 and \$174,760, respectively, to meet its current obligations. The Company had working capital deficit of \$(3,028) as of June 30, 2024, an increase of working capital of \$14,964 as compared to December 31, 2023. This increase in working capital was primarily driven by an increase in inventory of \$13,593 and a decrease in accounts payable of \$6,078 partially offset by an increase of income taxes payable of \$2,771, during the six months ended June 30, 2024.

The Company is an early-stage growth company, generating cash from revenues and deploying its capital to acquire and develop assets capable of producing additional revenues and earnings over both the immediate and long term. Capital is primarily being utilized for capital expenditures, facility improvements, strategic investment opportunities, product development and marketing, as well as customer, supplier, and investor and industry relations. The Company takes a cautious approach in allocating its capital to maximize its returns while ensuring appropriate liquidity. While inflation and higher interest rates have not yet materially impacted the Company's business, results of operations or financial statements, given current inflation and the uncertainty of the future economic environment, the Company has taken additional measures in monitoring and deploying its capital to minimize the negative impact on its operations and expansion plans.

Liquidity Requirements

Our short-term liquidity requirements consist primarily of funds necessary to pay for our acquisitions, to repay borrowings, maintain our operations and other general business needs. We believe that internally generated funds and other sources of liquidity discussed below will be sufficient to meet working capital needs, capital expenditures, payments of income tax payables and other business requirements for at least the next 12 months. We believe we will meet known or reasonably likely future cash requirements through the combination of cash generated from operating activities, available cash balances and available borrowings. If these sources of liquidity need to be augmented, additional cash requirements would likely be financed through the issuance of equity securities or additional borrowings; however, there can be no assurances that we will be able to obtain additional equity financing or debt financing on acceptable terms in the future.

Our long-term liquidity requirements consist primarily of completing additional acquisitions, scheduled debt payments, future payments of income tax payables, maintaining and expanding our operations and other general business needs. We expect to meet our long-term liquidity requirements through various sources of capital, which may include future debt or equity issuances, net cash provided by operations and other secured and unsecured borrowings. We believe that the foregoing sources of capital will provide sufficient funds for our operations, anticipated expansion and scheduled debt payments for the long-term. Our ability to fund our operating needs will depend on our future ability to continue to generate positive cash flow from operations and our ability to obtain debt or equity financing on acceptable terms.

Table of Contents

Credit Facility

On October 27, 2022, Verano and certain of its subsidiaries and affiliates from time-to-time party thereto (collectively, the "Borrowers"), entered into a Credit Agreement (the "2022 Credit Agreement") with Chicago Atlantic Admin, LLC ("Chicago Atlantic"), as administrative agent for the lenders, and the lenders from time-to-time party thereto (the "Lenders"), pursuant to which the Lenders advanced the Borrowers a \$350,000 senior secured term loan, all of which was used to repay the principal indebtedness outstanding under the Company's previous senior secured term loan credit facility. In connection with such repayment, such previous credit facility was terminated and is no longer in force or effect.

The 2022 Credit Agreement provides the Borrowers with the right, subject to conditions, to request an additional incremental term loan in the aggregate principal amount of up to \$100,000; provided that the Lenders elect to fund such incremental term loan. Beginning in October 2023, the loan requires scheduled amortization payments of \$350 per month and the remaining principal balance is due in full on October 30, 2026.

The 2022 Credit Agreement also provides the Borrowers with the right to (a) incur up to \$120,000 of additional indebtedness from third-party lenders secured by real estate excluded as collateral under the 2022 Credit Agreement, (b) incur additional mortgage financing from third-party lenders secured by real estate acquired after the closing date, and (c) upon the SAFE Banking Act or similar legislation making banking services available to U.S. cannabis companies being passed by the United States Congress, incur up to \$50,000 pursuant to a revolving credit facility from third-party lenders that is pari passu or subordinated to the 2022 Credit Agreement obligations, each of which are subject to customary conditions.

The obligations under the 2022 Credit Agreement are secured by substantially all of the assets of the Borrowers, excluding vehicles, specified parcels of real estate and other customary exclusions.

The 2022 Credit Agreement provides for a floating annual interest rate equal to the prime rate then in effect plus 6.50%, which rate may be increased by 3.00% upon an event of default that is not a material event of default or 6.00% upon a material event of default.

At any time, the Company may voluntarily prepay up to \$100,000 of the principal balance, subject to a one-time \$1,000 prepayment premium upon the first prepayment, and may prepay the remaining outstanding principal balance for a prepayment premium at varying rates based on the timing of any subsequent prepayments. The Borrowers may not voluntarily prepay more than \$100,000 of the principal balance without prepaying the entire outstanding principal balance of the loan.

The 2022 Credit Agreement includes customary representations and warranties and covenants and customary events of default, including, without limitation, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to material indebtedness, and events of bankruptcy and insolvency.

The 2022 Credit Agreement also includes customary negative covenants limiting the Borrowers' ability to incur additional indebtedness and grant liens that are not otherwise permitted, and the ability to enter into or consummate acquisitions or dispositions that are not otherwise permitted, among others. Additionally, the 2022 Credit Agreement requires the Borrowers to meet certain financial tests regarding minimum cash balances, minimum levels of Adjusted EBITDA (as defined in the 2022 Credit Agreement) and a minimum fixed charge coverage ratio.

As of June 30, 2024, the Company was in compliance with such covenants.

Permitted Partial Optional Prepayment and Lien Release

On April 30, 2024, the Company, made a Permitted Partial Optional Prepayment (as defined in the 2022 Credit Agreement) in the amount of \$50,000 pursuant to the 2022 Credit Agreement and paid \$1,000 prepayment premium in connection therewith.

In connection with such Permitted Partial Optional Prepayment, Chicago Atlantic and certain Lenders agreed to (a) release certain Borrowers from their obligations under, and as parties to, the 2022 Credit Agreement and related agreements (the "Released Borrowers") and (b) release all liens over the Released Borrowers' property, including real estate, held by Chicago Atlantic for the benefit of the Lenders, in each case, pursuant to a limited consent and waiver, dated as of April 29, 2024, by and among the Borrowers, certain of the Lenders party thereto and Chicago Atlantic.

Tax Liabilities

The Company has U.S. income tax payable liabilities. These income tax payable liabilities will require payment from our liquidity sources, and we believe we have sufficient liquidity for both short-term and long-term payments of our income tax payable liabilities and in addition to our other obligations.

Table of Contents

Sources and Uses of Cash

Cash Provided by (Used in) Operating Activities, Investing and Financing Activities

Net cash provided by (used in) operating, investing, and financing activities for the six months ended June 30, 2024 and 2023 were as follows:

	Six Months Ended June 30,						
	 2024		2023		\$ Change		
Net Cash Provided by Operating Activities	\$ 38,962	\$	40,740	\$	(1,778)		
Net Cash Used in Investing Activities	(28,215)		(14,369)		(13,846)		
Net Cash Used in Financing Activities	(55,470)		(8,643)		(46,827)		

Cash flows from Operating Activities. During the six months ended June 30, 2024 and 2023, the Company had net cash inflows of \$38,962 and \$40,740, respectively. The \$(1,778) decrease was mainly driven by an increase in inventory due to increased third party wholesales in select markets during the six months ended June 30, 2024 when compared to the six months ended June 30, 2023.

Cash Flows from Investing Activities. During the six months ended June 30, 2024 and 2023, the Company had net cash outflows of \$(28,215) and \$(14,369), respectively. The \$(13,846) decrease in net cash outflows during the six months ended June 30, 2024 compared to the six months ended June 30, 2023 is primarily driven by cash outflows related to the purchases of property, plant and equipment of \$(28,215) during the six months ended June 30, 2024, compared to purchases of property, plant and equipment of \$(16,541) during the six months ended June 30, 2023.

Cash Flows from Financing Activities. During the six months ended June 30, 2024 and 2023, the Company had net cash outflows of \$(55,470) and \$(8,643), respectively. The \$(46,827) decrease in net cash outflows during the six months ended June 30, 2024 compared to the six months ended June 30, 2023 was largely attributable to the Permitted Partial Optional Prepayment under the 2022 Credit Agreement during the six months ended June 30, 2024.

The Company has updated its capital expenditures guidance to a range of \$90,000 - \$130,000 for the year-ended December 31, 2024. The Company expects to strategically invest ahead of possible new adult-use and medical program launches, depending upon certain regulatory changes, and expanding current cultivation and processing capacity in existing markets.

Changes in or Adoption of Accounting Practices

Refer to the discussion of recently adopted/issued accounting pronouncements under Part I, Item 1, Notes to Unaudited Interim Condensed Consolidated Financial Statements, Note 1 - Overview and Basis of Presentation.

Critical Accounting Policies and Significant Judgements and Estimates

There were no material changes to our critical accounting policies and estimates from the information provided in "Management's Discussion and Analysis of Financial Condition and Results of Operations," included in the Form 10-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes to our market risk disclosures as set forth in Part II, Item 7A of the Form 10-K.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) are designed to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.

As required by Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (who is our principal executive officer) and Chief Financial Officer (who is our principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures, as of June 30, 2024, the end of the period covered by this Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Form 10-Q, our disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed by us in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the rules and forms of the Exchange Act and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures due to the material weaknesses in internal control over financial reporting identified as of December 31, 2023 and as described in Item 9A. Controls and Procedures in the Form 10-K. We believe, that a controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls systems are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, within a company have been detected.

Changes in Internal Control over Financial Reporting

We previously identified and disclosed material weaknesses in internal control over financial reporting as described in Item 9A. Controls and Procedures in the Form 10-K. These material weaknesses are currently in the process of being remediated, as of June 30, 2024. Other than the previously identified and disclosed plans to remediate the material weaknesses in internal control over financial reporting as described in Item 9A. Controls and Procedures in the Form 10-K, there have not been any changes in our internal control over financial reporting during the quarter ended June 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, the Company may be subject to legal proceedings, claims, investigations and government inquiries in the ordinary course of business. The Company has received, and may in the future continue to receive, claims from third parties.

Please see the Notes to Unaudited Interim Condensed Consolidated Financial Statements, Note 11 – Contingencies and Other – Claims and Litigation, which is incorporated herein by reference.

ITEM 1A. RISK FACTORS.

Part I, Item 1A. "Risk Factors" in our Form 10-K includes a discussion of our risk factors. There have been no material changes from the risk factors described in the Form 10-K. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future SEC filings.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

In June 2024, the Company's Board of Directors approved a Normal Course Issuer Bid (the "NCIB") that will be executed in accordance with the applicable rules and policies of Cooe and U.S. and Canadian securities laws. Pursuant to the NCIB, the Company may purchase up to an aggregate of 17,320,857 Subordinate Voting Shares (representing 5% of the issued and outstanding Subordinate Voting Shares at the time of the authorization), subject to a \$50 million limit. The purchases may be made from time to time over a period of 12 months ending June 13, 2025, unless such share or dollar limit is met sooner. During the quarter ended June 30, 2024, the Company did not purchase Subordinate Voting Shares under the NCIB.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Trading Plans

Aaron Miles, the Company's Chief Investment Officer, adopted a prearranged share trading plan with a brokerage firm on June 12, 2024. Mr. Miles' plan provides for the sale of 96,832 Subordinate Voting Shares between December 1, 2024 and December 1, 2025; provided, that such number of Subordinate Voting Shares reflects estimated tax withholdings and actual sale amounts may vary. Mr. Miles' trading plan was entered into during an open trading window and is intended to satisfy the affirmative defenses of Rule 10b5-1(c) under the Exchange Act and the Company's policies regarding insider transactions.

<u>Table of Contents</u>

ITEM 6. EXHIBITS

Exhibit Number	Description of Exhibit
3.1*	Articles of Verano Holdings Corp., dated February 11, 2021 (filed as Exhibit 3.1 to our Registration Statement on Form 10 filed on April 26, 2022 (File No. 000-56342) and incorporated herein by reference).
3.2*	Notice of Articles of Verano Holdings Corp., dated February 11, 2021 (filed as Exhibit 3.2 to our Registration Statement on Form 10 filed on April 26, 2022 (File No. 000-56342) and incorporated herein by reference).
31.1**	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
31.2**	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1***	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2***	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL Document)
* Previous	ly filed.

Previously filed.

^{**} Filed herewith

Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: August 7, 2024

VERANO HOLDINGS CORP.

By: /s/ George Archos

Name: George Archos

Title: Chief Executive Officer

By: /s/ Brett Summerer

Name: Brett Summerer

Title: Chief Financial Officer

CERTIFICATE OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, George Archos, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Verano Holdings Corp.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)) and 15d-15(f)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 7, 2024

/s/ George Archos

George Archos (Principal Executive Officer)

CERTIFICATE OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Brett Summerer, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Verano Holdings Corp.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(f)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 7, 2024

/s/ Brett Summerer

Brett Summerer (Principal Financial Officer)

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Verano Holdings Corp. (the "Company") for the three and six months ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, George Archos, Chief Executive Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 7, 2024

/s/ George Archos

George Archos (Principal Executive Officer)

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Verano Holdings Corp. (the "Company") for the three and six months ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Brett Summerer, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 7, 2024

/s/ Brett Summerer

Brett Summerer (Principal Financial Officer)